Dr. Lener is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
353 Lexington Avenue
Room 600
New York, NY 10016Phone+1 240-389-2381Fax+1 240-389-2381
Education & Training
Clinical Center at the National Institutes of HealthFellowship, National Institute of Mental Health, 2015 - 2018
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2011 - 2015
George Washington University School of Medicine and Health SciencesClass of 2011
University of PennsylvaniaB.A., Biological Basis of Behavior, 1996 - 2000
Certifications & Licensure
MD State Medical License 2015 - 2026
NY State Medical License 2013 - 2025
CO State Medical License 2021 - 2023- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 15 citationsThe effects of ketamine on typical and atypical depressive symptoms.Lawrence Park, David A. Luckenbaugh, S. J. Pennybaker, Matthew Hopkins, Ioline D. Henter
Acta Psychiatrica Scandinavica. 2020-11-01 - 22 citationsNeurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.Lawrence Park, Maura L. Furey, Allison C. Nugent, Cristan Farmer, Jessica Ellis
The International Journal of Neuropsychopharmacology. 2019-01-01 - 45 citationsAcute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder.Bashkim Kadriu, Philip W. Gold, David A. Luckenbaugh, Marc S. Lener, Elizabeth D. Ballard
Molecular Psychiatry. 2018-07-01
Journal Articles
- Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat DepressionLener MS, Kadriu B, Zarate C, Drugs, 2/14/2017
Authored Content
- F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
- F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
Professional Memberships
- Member
- Society of Biological PsychiatryMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
